Immunomodulatory Cell-Aggregate Biomaterial for Localized Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cell-based therapies struggle to provide long-lasting, localized immunomodulatory activity due to cell phenotypic changes and instability, leading to ineffective treatment of inflammatory diseases and conditions.
Innovation Solution
A biomaterial comprising aggregates of phenotypically stabilized cells, combined with biomaterial components, is developed for localized administration, providing sustained immunomodulation and reducing the need for systemic immunosuppressants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If living cells are used for immunomodulation, then immunomodulatory activity is provided, but cells change phenotype and undergo death over time, reducing treatment effectiveness
Solution Approach 1:
The patent extracts the essential immunomodulatory components from living cells (cell membranes, extracellular vesicles, or specific proteins) and incorporates them into a biomaterial scaffold. This separation allows the immunomodulatory activity to be maintained without the limitations of living cell viability and phenotypic stability.
Solution Approach 2:
The patent creates artificial copies of cell-based immunomodulatory systems using biomaterials that mimic the function of living cells. These biomaterial constructs replicate the immunomodulatory effects without requiring cellular metabolism or maintaining phenotypic stability over time.
2Reliability
If systemic immunosuppressants are administered, then immunomodulation is achieved, but global immunodepression occurs leading to infections and malignant tumors
Solution Approach 1:
The patent employs biomaterials that deliver immunomodulatory agents locally to specific tissues or organs. The biomaterial scaffold is designed to remain at the target site and release immunomodulatory components locally, achieving therapeutic effects without systemic immunodepression and associated side effects.
Solution Approach 2:
The biomaterial acts as an intermediary carrier that delivers immunomodulatory components to the target site. This intermediary system enables localized immunomodulation without requiring systemic administration of immunosuppressants, thereby avoiding global immunodepression.
3Object-affected harmful factors
If cell-based therapies are administered locally, then localized immunomodulation is achieved, but cells fail to provide long-lasting effect due to phenotypic changes and death
Solution Approach 1:
The patent prepares biomaterial constructs with pre-loaded immunomodulatory components before implantation. The biomaterial is designed to maintain structural integrity and release components over an extended period, ensuring long-lasting localized immunomodulation without relying on cell survival.
Solution Approach 2:
The patent creates composite biomaterial systems combining scaffold materials with immunomodulatory components. This composite structure provides both mechanical stability for long-term presence at the implantation site and sustained release of immunomodulatory agents, achieving durable localized treatment.
Data Source
AI summary
The present invention provides a biomaterial for immunomodulation comprising aggregates of phenotypically stabilized cells. Said biomaterial is meant to be preferentially administered in a limited location and provides immunomodulation for preventive or therapeutic purposes.It is also part of the present invention the process for production of the mentioned biomaterial and uses thereof. More specifically, the biomaterial for immunomodulation herein disclosed adds benefit in contexts of transplantation, chronic inflammation, autoimmune diseases, acute inflammation, cancer treatment, or in injured tissue regeneration.